US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

31.53

-0.0337-0.11%

Post-market: 31.26-0.2703-0.86%16:10 EDT

Volume:280

Turnover:9K

Market Cap:630.51K

PE:- -

High:31.53

Open:31.26

Low:31.26

Close:31.56

52wk High:35.56

52wk Low:25.40

Shares:20.00K

Float Shares:20.00K

Volume Ratio:0.82

T/O Rate:1.40%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Humana (HUM), Why Is It Back In The Spotlight?

Simply Wall St.

Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

EBR Systems advances FDA approval process for new WiSE manufacturing site

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

Ultragenyx price target raised to $35 from $32 at Barclays

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Ultragenyx confirms FDA approval of Fayuvi

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

Barclays downgrades Scholar Rock on valuation after FDA approval

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/XLVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XLVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","market":"US","secType":"STK","nameCN":"Corgi U.S. Healthcare 2x Daily ETF","latestPrice":31.5253,"timestamp":1790971200000,"preClose":31.559,"halted":0,"volume":280,"hourTrading":{"tag":"盘后","latestPrice":31.255,"preClose":31.5253,"latestTime":"16:10 EDT","volume":8,"amount":252.2024,"timestamp":1790971805196,"change":-0.2703,"changeRate":-0.008574,"amplitude":0},"delay":0,"changeRate":-0.0010678411863493653,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Market Closed","change":-0.0337,"latestTime":"10-02 16:00:00 EDT","open":31.255,"high":31.5253,"low":31.255,"amount":8760,"amplitude":0.008565,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":31.559,"nav":31.5,"aum":630000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.255,"preClose":31.5253,"latestTime":"16:10 EDT","volume":8,"amount":252.2024,"timestamp":1790971805196,"change":-0.2703,"changeRate":-0.008574,"amplitude":0},"volumeRatio":0.824986},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.824986,"shares":20000,"dividePrice":0,"high":31.5253,"amplitude":0.008565,"preClose":31.559,"low":31.255,"week52Low":25.3968,"pbRate":"--","week52High":35.56,"institutionHeld":0,"latestPrice":31.5253,"eps":0,"divideRate":0,"volume":280,"delay":0,"ttmEps":0,"open":31.255,"prevYearClose":25.46,"prevWeekClose":33.3274,"prevMonthClose":32.5588,"prevQuarterClose":32.5588,"fiveDayClose":33.3274,"twentyDayClose":34.2893,"sixtyDayClose":30.5197},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672779757","title":"Humana (HUM), Why Is It Back In The Spotlight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672779757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672779757?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:27","pubTimestamp":1790918866,"startTime":"0","endTime":"0","summary":"Humana (HUM) just outlined its 2027 Medicare Advantage lineup, highlighting $0 in-network primary care and labs, dental, vision and hearing benefits, and an expanded footprint for chronic condition special needs plans.\nHumana’s latest Medicare Advantage refresh lands after a strong run, with the share price up 43.56% year to date and a 1 year total shareholder return of 49.57%, although the 3 year and 5 year total shareholder returns remain in decline. This suggests recent momentum is...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","XLVX","LU0417517546.SGD","BK4588","LU0266013472.USD","LU0390134368.USD","IEHS","BK7500","UNHG","LU0211331839.USD","LU0070302665.USD","LU1983260115.SGD","SG9999014013.SGD","UNHW","BK4154","HUM.AU","LU0256863811.USD","IYH","LU0320765489.SGD","UNHU","LU0208291251.USD","HUM","IHF","BK7093","SG9999014005.SGD","BK4533","LU0348723411.USD","BK4566","LU0170899867.USD","UN","LNGR","LU1093756325.SGD","BK4585","LU0238689110.USD","XHS","FXH","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754056","title":"Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754056","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754056?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856000,"startTime":"0","endTime":"0","summary":"Clover’s portfolio combines high-choice PPO access and meaningful member benefits with a Clover Assistant-powered care modelWILMINGTON, Del., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372826/0/en/clover-health-s-2027-medicare-advantage-plans-emphasize-ppo-choice-preventive-care-and-member-value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0276348264.USD","LU0210536198.USD","LU2404859667.USD","IYG","MA","BK4534","LU0320765059.SGD","LU2552382132.HKD","LNGR","FXH","LU0868494617.USD","LU2462157665.USD","LU0345770993.USD","CGCV","LU0950375773.USD","LU2552382058.USD","STBQ","VFH","IE00BJJMRY28.SGD","LATR","CLOV","CA","BK4559","UN","XHS","UNHG","IPAY","HUM","IE000F7OJYX1.SGD","NOBL","IXJ","LU0210533765.USD","IE00B4JS1V06.HKD","IYH","LU0316494557.USD","UNHU","VHT","UYG","XLVX","FDFF","IE00BN29S564.USD","TCAF","IEHS","LU0061474960.USD","CHH","XLF","IHF","FNCL","UNHW","IE00B775H168.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672816387","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672816387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672816387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 02:03","pubTimestamp":1790791380,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","UN","LU0256863811.USD","LU0348723411.USD","LU1983260115.SGD","LNGR","LU0320765489.SGD","IHF","LU1093756325.SGD","XLVX","LU0211331839.USD","SG9999014013.SGD","LU0266013472.USD","IYH","UNHU","LU1093756168.USD","BK4588","LU0417517546.SGD","SG9999014005.SGD","UNHG","IEHS","LU0170899867.USD","XHS","HUM","BK4154","LU0208291251.USD","LU0238689110.USD","LU0390134368.USD","FXH","LU0070302665.USD","SG9999014021.USD","BK4533","BK4585","UNHW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671431772","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2671431772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671431772?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:17","pubTimestamp":1790695020,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLVX","LU0390134368.USD","LU0256863811.USD","LU1093756168.USD","LU0417517546.SGD","IHF","HUM","UN","BK4566","UNHU","LU0211331839.USD","LU0348723411.USD","UNHG","LU0170899867.USD","BK4154","LU0266013472.USD","LNGR","LU1983260115.SGD","LU0070302665.USD","XHS","SG9999014021.USD","BK4533","LU0238689110.USD","UNHW","FXH","IYH","BK4588","BK4585","IEHS","SG9999014013.SGD","LU0208291251.USD","SG9999014005.SGD","LU0320765489.SGD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","LU2324357040.USD","BK4007","TEVA","BK4585","BMED","IEIH","LU1983299246.USD","BK4559","IYH","MRNX","MRNY","BK4584","SYNB","BK4596","GNMX","IBB","BK4557","BBP","LABU","RSPH","BK4588","BK4566","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBPH","BMED","MRNX","TECB","MEDI","GDOC","GNMX","LABU","LFSC","IYH","MRNY","BK4007","BK4588","NVIB","FRTY","IDNA","XLVX","BBP","PSCH","IEIH","SYNB","RSPH","PINK","IBB","BK4585","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","EES","PSCH","FRTY","GDOC","IDNA","MRNX","BMED","IYH","XLVX","BK4588","LABU","BBP","TECB","GNMX","TBXU","SYNB","NVIB","IBB","LFSC","IEIH","BK4585","MRNY","RSPH","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4585","PINK","NVIB","PSCH","TBXU","BK4588","IBB","MRNY","SYNB","GDOC","GNMX","BMED","XLVX","LFSC","MESO","LABU","IYH","FRTY","MEDI","TECB","RSPH","BK4139","BBP","IEIH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147769","title":"Lucid Diagnostics advances Medicare reimbursement and coding infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147769","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147769?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:29","pubTimestamp":1790083753,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On September 22, 2026, Lucid Diagnostics announced key advances in payment, billing and codin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","FXH","HTEC","LU0708994859.HKD","BK4585","LU1267930490.SGD","LU0433182093.SGD","AGNG","IHI","XLVX","IEHS","LCID","CURE","LU1150488135.SGD","XHE","MEDI","SG9999014013.SGD","RXD","MHIG","JHMH","LU0203347892.USD","LUCD","BK4551","RSPH","IYH","LU0868494617.USD","REZ","XLVI","TMED","PSCH","LU0310800379.SGD","IE00B775SV38.USD","BMED","DVXV","IHF","LCIZ","LU0310799852.SGD","SG9999014039.USD","HCA","LNGR","LU1084165304.USD","BK4099","MHIP","PTH","BK4588","PINK","LCDL","TRUH","IE00B3S45H60.SGD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","PINK","BK4139","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","RARE","LABU","NVIB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","TBXU","FRTY","NVIB","MRNY","GDOC","AMRX","MRNX","BMED","BK4007","IEIH","BK4585","LFSC","SYNB","RSPH","IDNA","BBP","IBB","BK4588","PINK","LABU","MEDI","PSCH","XLVX","TECB","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBB","LABU","IDNA","RSPH","TECB","IYH","MRNY","BK4585","NVIB","BMED","FRTY","RARE","BBP","XLVX","ABEO","TBXU","MRNX","BK4588","PINK","LFSC","PSCH","SYNB","MEDI","GNMX","IEIH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","MEDI","BBP","SYNB","TBXU","IYH","BMED","IDNA","GNMX","GDOC","FRTY","MRNY","PSCH","BK4139","LABU","RARE","TECB","XLVX","BK4585","NVIB","MRNX","IBB","LFSC","BK4588","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","MRNX","TECB","MEDI","GDOC","NVIB","RSPH","BMED","IDNA","FRTY","GNMX","LABU","LFSC","PSCH","SYNB","NUVB","MRNY","IBB","TBXU","BK4585","XLVX","BK4007","BK4588","BBP","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963474","title":"Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963474?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:30","pubTimestamp":1789637420,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4588","BK4007","LFSC","GNMX","IBB","TECB","PINK","PSCH","XLVX","SYNB","TBXU","BK4585","GDOC","MRNX","BAYRY","FRTY","BMED","NVIB","MRNY","IDNA","IYH","IEIH","MEDI","LABU","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","BK4585","BMED","XBIX","IEIH","IYH","MRNX","MRNY","SYNB","GNMX","IBB","BBP","LABU","RSPH","BK4588","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","XLVX","TACU","NVIB","BMED","LFSC","IYH","LABU","FRTY","BBP","TSPA","MEDI","IEIH","TECB","GNMX","CDIG","PINK","MRNY","IBB","SYNB","GDOC","IDNA","RSPH","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GDOC","FRTY","BK4585","BFRI","XLVX","LFSC","BMED","MRNY","LABU","TBXU","TECB","SYNB","BK4588","NVIB","PINK","PSCH","BBP","IYH","GNMX","MEDI","IBB","IEIH","MRNX","RSPH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","GDOC","PSCH","SYNB","PINK","MRNY","NVIB","BMED","LABU","LFSC","IEIH","TBXU","IBB","IYH","IDNA","BK4588","GNMX","MRNX","BK4585","RSPH","FRTY","MEDI","TECB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","MRNX","BMED","GNMX","LFSC","IEIH","XLVX","SRRK","RSPH","MEDI","IBRN","MRNY","BK4588","THNR","BBP","GDOC","BK4585","IDNA","PINK","SYNB","NVIB","LABU","TECB","BK4139","PSCH","IYH","TBXU","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}